^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Excerpt:
...These include mutation in RAS, BRAF, PI3KCA; amplification of HER2, MET and loss of PTEN expression, all of which are implicated in resistance to anti-EGFR treatment....
Trial ID:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Excerpt:
...amplification of the MET proto-oncogene is associated with acquired resistance in patients who do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident.
DOI:
10.1158/2159-8290.CD-12-0558